The company is working on treatments for breast cancer and solid tumours, based on research at University of Toronto and the Centre for the Commercialization of Antibodies and Biologics.
Canada-based cancer-focused biopharmaceutical company ImmunoBiochem raised an undisclosed sum in a funding round on Monday co-led by assorted, unnamed angel investors.
The round was co-led by an undisclosed backer, named as ImmunoBiochem’s “founding investor”, though details could be not ascertained. The company has moved into JLabs at Toronto, a life sciences incubator operated by healthcare firm Johnson & Johnson.
ImmunoBiochem is developing therapies for solid tumours and company currently has two preclinical drug candidates in its pipeline. The company…